ASH 2020 | QUAZAR AML-001: impact of MRD status on CC-486 efficacy in AML

Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses findings from an analysis of the Phase III QUAZAR AML-001 trial (NCT01757535) of CC-486 in acute myeloid leukemia (AML) patients in first remission following intensive chemotherapy. Many patients who achieve remission will go on to relapse. Measurable residual disease (MRD) negativity is an important prognostic marker in this setting. The QUAZAR AML-001 maintenance trial assessed the impact of MRD status on survival following CC-486 treatment for AML patients. The study showed significant prolongation of overall and relapse-free survival with CC-486 use compared to placebo, regardless of baseline MRD status. Use of CC-486 increased the duration of MRD negativity and induced a higher rate of conversion to MRD negativity in baseline MRD-positive patients. In both arms, MRD negativity was associated with significantly longer survival outcomes. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.